My research laboratory studies the molecular epidemiology of cardiovascular disease, utilizing metabolomic, genomic and bioinformatics methods in a "systems biology" approach to identify novel biomarkers and mechanisms of cardiometabolic disease pathogenesis. The laboratory encompasses a statistical analytic component, a clinical research component, as well as a wet lab component for genomic analyses. We work on several cardiometabolic phenotypes, including coronary artery disease, acute coronary syndrome, cardiovascular events, aortic stenosis, aortic aneurysm, pulmonary hypertension, type II diabetes, and heart failure, . We are involved in molecular profiling in cardiometabolic cohorts including CATHGEN (N=9500 individuals referred to cardiac catheterization), EPGEN (N=2500 individuals undergoing electrophysiologic procedures); and in clinical trial biorepositories through collaborations with the Duke Clinical Research Institute (DCRI) including Trilogy (clinical trial of acute coronary syndrome), Navigator (clinical trial to prevent transition from prediabetes to diabetes), and PROMISE (clinical trial of imaging in suspected CAD). More recently, we have expanded our molecular epidemiology efforts to identify disease biomarkers in global populations and are currently conducting a small prospective study of metabolic and genomic biomarkers of type II DM and CAD in Gurgaon, India in collaboration with Medanta Hospital through collaborations with the Duke Global Health Institute (DGHI). Through work with the Duke Heart Center, we also care of patients with hereditary cardiovascular disorders in the Duke Adult Cardiovascular Genetics Clinic (Ruth Lehan, genetic counselor). Our work has resulted in the identification of novel CAD genes; metabolic biomarkers that predict incident CVD events; and novel pathways of CVD event pathogenesis.